All In Biotech

Drug Trial Radar · NCT03900325

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy of Nimacimab in Patients With Diabetic Gastroparesis

A Single-Blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy of Nimacimab in Patients With Diabetic Gastroparesis

Last checked: Nov 19, 2026Latest source record: Jan 18, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

6

Actual

Start

Aug 1, 2019

Primary completion

Jan 2020

Study completion Apr 2020

Sponsor

Lead sponsor
Bird Rock Bio, Inc.Industry
Sponsor type
Industry
First posted
Apr 3, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single blind phase 2a study to evaluate the safety, tolerability, pharmacokinetics, and exploratory efficacy of nimacimab in patients with diabetic gastroparesis.

Conditions

  • Diabetic Gastroparesis

Interventions

  • NimacimabDrug

    2.5 mg/kg

  • PlaceboDrug

    0.9% sodium chloride

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency of clinically significant laboratory abnormalitiesTime frame: Day 38
  2. Frequency of clinically significant vital signsTime frame: Day 38
  3. Frequency of clinically significant ECGsTime frame: Day 38

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Panax Clinical Research

    Miami, Florida

  • International Research Associates, LLC

    Miami, Florida

  • PRN of Kansas

    Wichita, Kansas

  • Mayo Clinic

    Rochester, Minnesota

  • ClinSearch

    Chattanooga, Tennessee

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.